OS endpoint focus will realign industry to “ultimate goal” [Yahoo! Finance]
Immuneering Corporation - Class A (IMRX)
Company Research
Source: Yahoo! Finance
However, the US Food and Drug Administration (FDA) has made a bid to set OS's key role in oncology in stone – debuting industry draft guidance recommending it as a key pre-specified endpoint in all cancer clinical trials. In a statement to Clinical Trials Arena , the US regulator noted that it is taking this course to ensure that “the pursuit of efficacy endpoints does not overshadow critical safety concerns,” which are rife in the oncology sector due to the aggressive nature of its associated therapies. This is particularly true for hard-to-treat malignancies such as pancreatic cancer, which the FDA specifically mentions in its guidance. The agency likely calls out pancreatic cancer due to its strong reliance on toxic treatment regimens like chemotherapy in the first line, which can cause patient deaths before the disease takes hold. Meanwhile, the new guidance also states that trials must now “plan for survival assessment upfront, with specific attention to interim analyses f
Show less
Read more
Impact Snapshot
Event Time:
IMRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMRX alerts
High impacting Immuneering Corporation - Class A news events
Weekly update
A roundup of the hottest topics
IMRX
News
- Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Immuneering to Present at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- Immuneering (NASDAQ:IMRX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IMRX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</aMarketBeat
- Immuneering (NASDAQ:IMRX) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.MarketBeat
- Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
IMRX
Earnings
- 11/12/25 - Miss
IMRX
Sec Filings
- 11/12/25 - Form 10-Q
- 11/12/25 - Form 8-K
- 10/21/25 - Form SCHEDULE
- IMRX's page on the SEC website